TIFFANY ANDRY: Open Payments
NPI 1316233067 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,998 in 96 payments from 15 companies in 2025. Trend: 2023 $2,320 · 2024 $2,648 · 2025 $2,998
Food & beverage: $2,998
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $553 |
| Janssen Pharmaceuticals, Inc | 13 | $499 |
| ABBVIE INC. | 23 | $469 |
| Neurocrine BioSciences, Inc. | 10 | $359 |
| Vanda Pharmaceuticals Inc. | 7 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $228 |
| Axsome Therapeutics, Inc. | 2 | $223 |
| E.R. Squibb & Sons, L.L.C. | 3 | $166 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $66 |
| Janssen Scientific Affairs, LLC | 1 | $64 |
Products named: REXULTI, INGREZZA, VRAYLAR, INVEGA SUSTENNA, SPRAVATO, FANAPT, TRINTELLIX, Auvelity.
Industry payments across AL — which companies pay providers there.
